Literature DB >> 1712285

Guanidino compounds that are increased in hyperargininemia inhibit GABA and glycine responses on mouse neurons in cell culture.

P P De Deyn1, B Marescau, R L Macdonald.   

Abstract

The effects of arginine, homoarginine, alpha-keto-delta-guanidinovaleric acid and argininic acid (guanidino compounds that were found to be increased in hyperargininemia) were evaluated on responses to gamma-aminoburtyric acid (GABA) and glycine (Gly) on mouse neurons in primary dissociated cell culture. GABA and Gly were applied iontophoretically and intracellular microelectrode recording techniques were used. The guanidino compounds rapidly and reversibly inhibited both GABA and Gly responses. The guanidino compounds inhibited GABA responses in a concentration-dependent manner and inhibited Gly responses at a concentration of 10 mM. Argininic acid was the most potent in reducing inhibitory amino acid responses, followed in decreasing potency by alpha-keto-delta-guanidinovaleric acid, homoarginine and arginine. The guanidino compounds were equally potent in decreasing Gly and GABA responses. Co-application of CGS 9896, a benzodiazepine receptor antagonist, did not antagonize the guanidino compound-induced inhibition of GABA responses. These findings suggest that the guanidino compounds inhibited responses to the inhibitory neurotransmitters GABA and Gly by blocking the chloride channel. This effect might underlie the in vivo epileptogenicity of some of the guanidino compounds and might contribute to the pathogenesis of seizures in hyperargininemia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712285     DOI: 10.1016/0920-1211(91)90081-p

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  8 in total

1.  Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma.

Authors:  Christopher S Hackett; David A Quigley; Robyn A Wong; Justin Chen; Christine Cheng; Young K Song; Jun S Wei; Ludmila Pawlikowska; Yun Bao; David D Goldenberg; Kim Nguyen; W Clay Gustafson; Sundari K Rallapalli; Yoon-Jae Cho; James M Cook; Serguei Kozlov; Jian-Hua Mao; Terry Van Dyke; Pui-Yan Kwok; Javed Khan; Allan Balmain; QiWen Fan; William A Weiss
Journal:  Cell Rep       Date:  2014-10-23       Impact factor: 9.423

Review 2.  Clinical, biochemical, and molecular spectrum of hyperargininemia due to arginase I deficiency.

Authors:  Fernando Scaglia; Brendan Lee
Journal:  Am J Med Genet C Semin Med Genet       Date:  2006-05-15       Impact factor: 3.908

3.  Pathogenesis of ventilator-induced lung injury: metabolomics analysis of the lung and plasma.

Authors:  Yanfei Mao; Zhixin Ma; Chufan Xu; Zhou Lv; Wenwen Dong; Xinru Liu
Journal:  Metabolomics       Date:  2022-08-04       Impact factor: 4.747

Review 4.  The Role of Preclinical Models in Creatine Transporter Deficiency: Neurobiological Mechanisms, Biomarkers and Therapeutic Development.

Authors:  Elsa Ghirardini; Francesco Calugi; Giulia Sagona; Federica Di Vetta; Martina Palma; Roberta Battini; Giovanni Cioni; Tommaso Pizzorusso; Laura Baroncelli
Journal:  Genes (Basel)       Date:  2021-07-24       Impact factor: 4.096

5.  N omega-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin.

Authors:  J P Cobb; C Natanson; W D Hoffman; R F Lodato; S Banks; C A Koev; M A Solomon; R J Elin; J M Hosseini; R L Danner
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

6.  Organic and Peptidyl Constituents of Snake Venoms: The Picture Is Vastly More Complex Than We Imagined.

Authors:  Alejandro Villar-Briones; Steven D Aird
Journal:  Toxins (Basel)       Date:  2018-09-26       Impact factor: 4.546

7.  Human cytosolic transaminases: side activities and patterns of discrimination towards physiologically available alternative substrates.

Authors:  Francesco Caligiore; Erika Zangelmi; Carola Vetro; Takfarinas Kentache; Joseph P Dewulf; Maria Veiga-da-Cunha; Emile Van Schaftingen; Guido Bommer; Alessio Peracchi
Journal:  Cell Mol Life Sci       Date:  2022-07-14       Impact factor: 9.207

8.  AAV-based gene therapy prevents neuropathology and results in normal cognitive development in the hyperargininemic mouse.

Authors:  E K Lee; C Hu; R Bhargava; R Ponnusamy; H Park; S Novicoff; N Rozengurt; B Marescau; P De Deyn; D Stout; L Schlichting; W W Grody; S D Cederbaum; G S Lipshutz
Journal:  Gene Ther       Date:  2013-02-07       Impact factor: 5.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.